Market Overview

UPDATE: Piper Jaffray Downgrades Trius Therapeutics Following Cubist Acquisition

Related TSRX
What Investors Should Be Watching In The Antibiotic Space
Mid-Afternoon Market Update: Fed Leaves Rates Unchanged; Green Dot Rises

In a report published on Wednesday, Piper Jaffray analyst Edward Tenthoff downgraded Trius Therapeutics (NASDAQ: TSRX) from Overweight to Neutral and raised the price target from $11.00 to $14.82.

In the report, Piper Jaffray stated, "Yesterday, Cubist (CBST) announced the acquisition of Trius for $13.50 in cash plus one non-tradeable $2.00 contingent value right (CVR). Under the terms of the CVR, each TSRX shareholder will receive $1.00 if net tedizolid sales in the U.S., Canada and Europe reach $125 million in 2016 and up to another $1.00, paid on a pro rata basis, for the next $10 million in 2016 net sales up to $135 million. We presently forecast 2016 tedizolid sales of $188 million, so we see a good chance that the full $2.00 CVR will be paid out. Applying an 18% discount rate back through today, we arrive at present CVR value of $1.32." 

Trius Therapeutics closed Tuesday at $11.71.

Latest Ratings for TSRX

Aug 2013Aegis CapitalDowngradesBuyHold
Aug 2013GuggenheimDowngradesBuyNeutral
Jul 2013PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for TSRX
View the Latest Analyst Ratings

Posted-In: Edward Tenthoff PiperJaffrayAnalyst Color Downgrades Analyst Ratings


Related Articles (TSRX)

View Comments and Join the Discussion!

Partner Center